Fig. 2
Exacerbation of facial dermatitis with swelling occurred 15 h after initiation of abrocitinib treatment, manifested as diffuse facial swelling, erythema and exudation on the forehead and nostrils
Fig. 2 | Allergy, Asthma & Clinical Immunology